Dramatic, durable response to therapy in gBRCA2-mutated pancreas neuroendocrine carcinoma: opportunity and challenge

[1]  Jie Gao,et al.  Genomic characterization reveals distinct mutation landscapes and therapeutic implications in neuroendocrine carcinomas of the gastrointestinal tract , 2022, Cancer communications.

[2]  C. Pritchard,et al.  BRCA2 Alterations in Neuroendocrine/Small-Cell Carcinoma Prostate Cancer: A Case Series. , 2022, JCO precision oncology.

[3]  M. Papotti,et al.  Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms , 2022, Endocrine Pathology.

[4]  V. Iyer,et al.  Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis , 2022, Nature Genetics.

[5]  M. Kanda,et al.  Comprehensive Genomic Profiling of Neuroendocrine Carcinomas of the Gastrointestinal System , 2021, Cancer discovery.

[6]  S. Knappskog,et al.  The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms , 2021, Endocrine-related cancer.

[7]  M. Berger,et al.  Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes , 2021, Cancer.

[8]  NCCN Guidelines® Updates: Neuroendocrine and Adrenal Tumors , 2021, Journal of the National Comprehensive Cancer Network.

[9]  A. Tutt,et al.  Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance , 2021, Nature Communications.

[10]  K. Goldberg,et al.  FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer. , 2021, The oncologist.

[11]  J. Reis-Filho,et al.  Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy , 2020, Nature Cancer.

[12]  P. Philip,et al.  Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma , 2020, ESMO Open.

[13]  Y. Bang,et al.  Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. , 2020, The Lancet. Oncology.

[14]  S. Gulati,et al.  Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. , 2020, The Lancet. Oncology.

[15]  G. Mills,et al.  Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models , 2020, Nature Communications.

[16]  N. Schultz,et al.  Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection , 2020, Clinical Cancer Research.

[17]  L. Shen,et al.  Etoposide and cisplatin versus irinotecan and cisplatin as the first‐line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study , 2020, Cancer.

[18]  Y. Drew,et al.  Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC) , 2019, Annals of Oncology.

[19]  R. Ramlau,et al.  Significance of BRCA1 expression in breast and ovarian cancer patients with brain metastasis - A multicentre study. , 2019, Advances in medical sciences.

[20]  S. Loi,et al.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. , 2017, New England Journal of Medicine.

[21]  Joon-Oh Park,et al.  Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. , 2019, The New England journal of medicine.

[22]  S. Ramaswamy,et al.  A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models , 2018, Oncotarget.

[23]  Gabe S. Sonke,et al.  Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer , 2018, The New England journal of medicine.

[24]  W. Eiermann,et al.  Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation , 2018, The New England journal of medicine.

[25]  H. Sorbye,et al.  Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases , 2018, Cancer.

[26]  E. Swisher,et al.  Somatic Reversion of Germline BRCA2 Mutation Confers Resistance to Poly(ADP-ribose) Polymerase Inhibitor Therapy. , 2018, JCO precision oncology.

[27]  T. Taxter,et al.  Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations. , 2018, JCO precision oncology.

[28]  P. Nelson,et al.  Polyclonal BRCA2 Reversion Mutations Detected in Circulating Tumor DNA After Platinum Chemotherapy in a Patient With Metastatic Prostate Cancer. , 2018, JCO precision oncology.

[29]  Shridar Ganesan,et al.  Tumor Suppressor Tolerance: Reversion Mutations in BRCA1 and BRCA2 and Resistance to PARP Inhibitors and Platinum. , 2018, JCO precision oncology.

[30]  J. Sarkaria,et al.  Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma , 2017, Molecular Cancer Therapeutics.

[31]  L. Borsu,et al.  Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer , 2017, Clinical Cancer Research.

[32]  Lincoln D. Stein,et al.  Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma , 2017, JAMA oncology.

[33]  V. Seshan,et al.  FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing , 2016, Nucleic acids research.

[34]  Donavan T. Cheng,et al.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.

[35]  Ayala Hubert,et al.  Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[37]  A. McKenna,et al.  Absolute quantification of somatic DNA alterations in human cancer , 2012, Nature Biotechnology.

[38]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[39]  S. Burma,et al.  PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. , 2010, Cancer research.

[40]  H. Ueno,et al.  Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. , 2010, Japanese journal of clinical oncology.

[41]  B. Preston,et al.  Case Series , 2010, Toxicologic pathology.

[42]  G. Petersen,et al.  Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  F. Couch,et al.  Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers , 2008, Nature.

[44]  Jorge S. Reis-Filho,et al.  Resistance to therapy caused by intragenic deletion in BRCA2 , 2008, Nature.

[45]  L. Collette,et al.  Prophylactic cranial irradiation in extensive small-cell lung cancer. , 2007, The New England journal of medicine.

[46]  Kh.D. Islamov.  REVERSION MUTATIONS IN BRCA1 AND BRCA2 AND RESISTANCE TO PARP INHIBITORS AND PLATINUM , 2019, EurasianUnionScientists.

[47]  O. Basturk,et al.  Poorly Differentiated Neuroendocrine Carcinoma of the Pancreas , 2015 .

[48]  J. Beijnen,et al.  Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699) , 2014, Pharmaceutical Research.

[49]  Naoki Ishiguro,et al.  A MULTICENTRE STUDY , 2010 .